Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts

Front Immunol. 2023 Nov 8:14:1259197. doi: 10.3389/fimmu.2023.1259197. eCollection 2023.

Abstract

Introduction: The rVSVDG-ZEBOV-GP (Ervebo®) vaccine is both immunogenic and protective against Ebola. However, the vaccine can cause a broad range of transient adverse reactions, from headache to arthritis. Identifying baseline reactogenicity signatures can advance personalized vaccinology and increase our understanding of the molecular factors associated with such adverse events.

Methods: In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination.

Results and discussion: We analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach revealed 22 key genes associated with adverse events such as local reactions, fatigue, headache, myalgia, fever, chills, arthralgia, nausea, and arthritis, providing insights into potential biological mechanisms linked to vaccine reactogenicity.

Keywords: Ebola; adverse events; baseline gene signatures; data integration; machine learning; personalized vaccinology; rVSVDG-ZEBOV-GP vaccine; vaccine safety.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Viral
  • Arthritis* / etiology
  • Clinical Trials, Phase I as Topic
  • Ebola Vaccines* / adverse effects
  • Ebolavirus* / genetics
  • Headache
  • Hemorrhagic Fever, Ebola*
  • Humans
  • Vaccination / adverse effects
  • Vaccination / methods

Substances

  • Antibodies, Viral
  • Ebola Vaccines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the Innovative Medicines Initiative 2 Joint Undertaking under the VSV-EBOVAC (grant number 115842) and VSV-EBOPLUS (grant number 116068) projects within the Innovative Medicines Initiative Ebola+ program and also by FAPESP (grant number 18/14933-2). Development of the dcRT-MLPA probe sets was funded by GC6-74 (grant number 37772) and ADITEC (grant number 280873). Conduction of the North American trial was funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201500002C.